Search results
Showing 8601 to 8650 of 8905 results
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Home News Podcasts Innovation in action: Inside NICE's HTA Lab Podcasts 30 July 2025 Listen About this episode Our Health Technology Assessment
Home News Podcasts Treating type 2 diabetes with SGLT-2 inhibitors Podcasts 25 August 2025 Listen About this episode In this episode, we discuss
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.
Patients to receive medicines 3 to 6 months faster under 10-Year Health Plan
NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.
Final decision on cerliponase alfa for Batten disease treatment confirmed
In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid lipofuscinosis type 2 (CLN2), a rare and life-limiting form of Batten disease.
Hundreds with rare inherited eye disease to benefit after NICE recommends treatment
NICE recommends idebenone for Leber's hereditary optic neuropathy following clinical evidence of vision improvement.
NICE approves first immunotherapy combination for endometrial cancer
Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, following our recommendation of pembrolizumab (Keytruda) in final draft guidance published today.
After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
NICE provisionally recommends leadless implantable pacemaker in draft guidance
A procedure for people with slow heart rhythms could be used more widely after it was recommended for NHS use in draft guidance.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
Home News Podcasts NICE's prioritisation board: focus on what matters most Podcasts 27 June 2025 Listen About this episode In this episode
Four AI technologies conditionally recommended to help detect undiagnosed fragility fractures
The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans.
NICE responds to publication of the government's Life Sciences Sector Plan
We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.
The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition.
NICE leads the way in approving breakthrough treatment for multiple myeloma
People in England will become the first in the world to receive belantamab mafodotin for this indication following our recommendation and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year.
Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.
Learn more about our updated maternal and child nutrition guideline
Home News Podcasts Learn more about our updated maternal and child nutrition guideline Podcasts 30 May 2025 Listen About this episode We're
Home News Podcasts Will robotic-assisted surgery change NHS practice forever? Podcasts 30 April 2025 Listen About this episode In this episode
Dr Sarah Byron discusses how NICE is transforming to ensure more digital health technologies are adopted by the NHS.
Over 4,200 people set to benefit after we recommend daily pill to treat rare chronic kidney disease
New treatment sparsentan has been found to slow down the progression of kidney damage, which will change people’s lives for the better.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
Up to 1,000 women a year could benefit from new at-home treatment for endometriosis
Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.
AI skin cancer detection system gets green light for conditional NHS use
An artificial intelligence system for potential skin cancer has been conditionally recommended for use in the NHS for the next three years while further evidence is collected.
Health inequalities - an update to NICE's methods for health technology evaluation
Our new modular update focuses on how we consider health inequalities when evaluating technologies for use in the NHS, and how you can get involved in suggesting future updates.
Technology recommended for people with chronic tic disorders and Tourette syndrome
Final guidance recommends one digital therapy to help children and young people manage their condition.
New guideline will help cut falls and related hospital admissions for older and at-risk people
Personalised assessments that consider factors including the hazards in a person’s home, and their previous medical history will help reduce falls in older and at-risk people, according to a new NICE guideline.
Cutting-edge robotic surgery gets green light as 11 systems are recommended
Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
Updated pneumonia guidelines for babies and children with mild pneumonia
Babies and children between the ages of three months and 11-years-old with pneumonia should be offered a three-day rather than five-day course of antibiotics, according to a new draft NICE guideline.
Millions of people living with long-term neurological conditions across England face inconsistent access to vital rehabilitation services, according to NICE.
Home News Podcasts Navigating the future - AI at NICE Podcasts 28 February 2025 Listen About this episode Dr Pall Jonsson, programme director
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
Endometriosis - learn more about NICE's guideline for this chronic condition
Home News Podcasts Endometriosis - learn more about NICE's guideline for this chronic condition Podcasts 25 March 2025 Listen About this episode
Home News Podcasts NICE's positive recommendations for lung cancer treatments Podcasts 20 January 2025 Listen About this episode We're joined
First-ever NHS treatment approved for advanced Hodgkin lymphoma
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Changes approved to the routing criteria for highly specialised technologies
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
Annual BMI checks recommended for adults with long-term conditions
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.